Neurofibromatosis type 2 is the less common form of neurofibromatosis. This condition is typically characterized by the development of benign tumors called schwannomas that grow along the eighth ...

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma ...

Neurofibromatosis type 2 (NF2) is an autosomal‐dominant disorder characterised by the development of multiple tumours, most notably bilateral vestibular schwannomas. These benign tumours originate ...

Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs).

Atypical manifestation of neurofibromatosis type 2 (NF2) in a 10-year-old boy was recently reported in Eye. 1 I would like to present another 10-year-old child with the atypical presentation of Horner ...

Neurofibromatosis type 2 is caused by a change in the NF2 gene located on chromosome 22. This gene encodes a protein known as merlin. Mutations in the NF2 gene disrupt the function of merlin, which is ...

The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ...

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 trial ...

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic ...

Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects around 1 in 25,000 individuals. In about half of these people, the condition is inherited, while the other half develop a ...

Neurofibromatosis type 2 (NF2) is much less common than NF1, affecting about 1 in 25,000 people worldwide regardless of sex or ethnicity. The disorder is characterized by the development of benign ...